7 analysts have shared their evaluations of Halozyme Therapeutics (NASDAQ:HALO) during the recent three months, expressing a mix of bullish and bearish perspectives.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Analysts have set 12-month price targets for Halozyme Therapeutics, revealing an average target of $52.43, a high estimate of $72.00, and a low estimate of $40.00. Observing a downward trend, the current average is 2.46% lower than the prior average price target of $53.75.

Investigating Analyst Ratings: An Elaborate Study

The perception of Halozyme Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Halozyme Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Halozyme Therapeutics analyst ratings.

About Halozyme Therapeutics

Halozyme Therapeutics's Financial Performance

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Net Margin: Halozyme Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 37.88%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Halozyme Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 40.9% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): Halozyme Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of 4.42%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: Halozyme Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 6.01, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

What Are Analyst Ratings?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.